Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer: A Randomized Clinical Trial

In this Phase II trial (n=169), addition of the IDO1 pathway inhibitor indoximod to a taxane did not improve progression-free survival in patients with ERBB2-negative metastatic breast cancer (median 6.8 versus 9.5 months with taxane alone; not statistically significant).

JAMA Oncology